Shopping Cart
Remove All
Your shopping cart is currently empty
WNK-IN-11 (Allosteric WNK Kinase Inhibitor) is an allosteric With-No-Lysine (WNK) kinase inhibitor,WNK1(IC50 : 4 nM)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $84 | In Stock | In Stock | |
| 5 mg | $190 | In Stock | In Stock | |
| 10 mg | $312 | In Stock | In Stock | |
| 25 mg | $526 | In Stock | In Stock | |
| 50 mg | $759 | In Stock | In Stock | |
| 100 mg | $1,070 | In Stock | In Stock | |
| 500 mg | $2,130 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $209 | In Stock | In Stock |
| Description | WNK-IN-11 (Allosteric WNK Kinase Inhibitor) is an allosteric With-No-Lysine (WNK) kinase inhibitor,WNK1(IC50 : 4 nM) |
| Targets&IC50 | WNK1:4 nM |
| In vitro | WNK-IN-11 (compound 11) demonstrates potent activity with an IC50 value of less than 2 μM in the OSR1 phosphorylation assay, exhibits reasonable water solubility, and shows relatively high microsomal clearance. It functions through ATP noncompetitive inhibition. When tested against a comprehensive panel of 440 human kinases at 10 μM, 2500-fold higher than the enzyme's IC50, WNK-IN-11 exhibits high selectivity, with significant off-target inhibition only against BTK and the feline encephalitis virus-related (FER) kinase, neither of which are involved in blood pressure regulation. This specificity highlights its potential as a targeted therapeutic agent, likely due to its predicted allosteric binding outside the conserved ATP-pocket region. |
| Synonyms | Allosteric WNK Kinase Inhibitor |
| Molecular Weight | 462.4 |
| Formula | C21H21Cl2N5OS |
| Cas No. | 2123489-30-3 |
| Smiles | CNc1nc(cs1)-c1cc(C(=O)N2CCN(Cc3ccc(Cl)cc3)CC2)c(Cl)cn1 |
| Relative Density. | 1.407 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: Insoluble DMSO: 150 mg/mL (324.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.